{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:21:52Z","timestamp":1788258112804,"version":"build-2803163510"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jpsychires.2020.06.013","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T12:09:13Z","timestamp":1596110953000},"page":"222-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"129","author":[{"given":"Erasmo","family":"Saucedo Uribe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Carranza Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Fernanda","family":"Guerrero Medrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Iscely","family":"Garc\u00eda Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neri Alejandro","family":"\u00c1lvarez Villalobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor Daniel","family":"Acu\u00f1a Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"M\u00e9ndez Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Mill\u00e1n Alan\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar Marcelo","family":"Hinojosa Cavada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Alberto","family":"Z\u00fa\u00f1iga Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan Mauricio","family":"Fern\u00e1ndez Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2020.06.013_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.schres.2017.03.020","article-title":"A novel approach to measuring response and remission in schizophrenia in clinical trials","volume":"190","author":"Aboraya","year":"2017","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.jpsychires.2020.06.013_bib2","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","article-title":"Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia a randomized clinical trial","volume":"72","author":"Berwaerts","year":"2015","journal-title":"JAMA Psychiatr."},{"issue":"2","key":"10.1016\/j.jpsychires.2020.06.013_bib3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res. Synth. Methods"},{"issue":"5","key":"10.1016\/j.jpsychires.2020.06.013_bib4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/2045125314540297","article-title":"The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal","volume":"4","author":"Brissos","year":"2014","journal-title":"Therapeut. Adv. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2020.06.013_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/B978-0-12-800981-9.00002-X","article-title":"Chapter 2 - a review of the epidemiology of schizophrenia","volume":"23","author":"Brown","year":"2016","journal-title":"Handb. Behav. Neurobiol."},{"key":"10.1016\/j.jpsychires.2020.06.013_bib6","series-title":"Causes of the Excess Mortality of Schizophrenia","author":"Brown","year":"1994"},{"issue":"2","key":"10.1016\/j.jpsychires.2020.06.013_bib7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/wps.20128","article-title":"Risks of all-cause and suicide mortality in mental disorders: a meta-review","volume":"13","author":"Chesney","year":"2014","journal-title":"World Psychiatr."},{"key":"10.1016\/j.jpsychires.2020.06.013_bib8","series-title":"Schizophrenia Treatment in the Developing World\u00a0: an Interregional and Multinational Cost-Effectiveness Analysis","author":"Chisholm","year":"2008"},{"key":"10.1016\/j.jpsychires.2020.06.013_bib9","series-title":"Review Manager (RevMan)","year":"2014"},{"key":"10.1016\/j.jpsychires.2020.06.013_bib10","first-page":"519","article-title":"Negative symptoms in Schizophrenia\u00a0: a review and clinical guide for recognition","volume":"16","author":"Correll","year":"2020","journal-title":"Assess. Treat."},{"issue":"5","key":"10.1016\/j.jpsychires.2020.06.013_bib11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4088\/JCP.11m07074","article-title":"Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres","volume":"73","author":"Covell","year":"2012","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2020.06.013_bib12","volume":"vols. 15\u201322","author":"De Hert","year":"2009"},{"issue":"3","key":"10.1016\/j.jpsychires.2020.06.013_bib13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Contr. Clin. Trials"},{"key":"10.1016\/j.jpsychires.2020.06.013_bib14","series-title":"Treatment of Patients with Schizophrenia","author":"Dixon","year":"2010"},{"issue":"7109","key":"10.1016\/j.jpsychires.2020.06.013_bib15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Br. Med. J."},{"issue":"Suppl. 52","key":"10.1016\/j.jpsychires.2020.06.013_bib16","article-title":"Second-generation antipsychotic long-acting injections: systematic review","volume":"195","author":"Fleischhacker","year":"2009","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jpsychires.2020.06.013_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1461145711001076","article-title":"A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia","volume":"15","author":"Fleischhacker","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2020.06.013_bib18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.schres.2017.04.004","article-title":"Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder","volume":"192","author":"Fu","year":"2018","journal-title":"Schizophr. Res."},{"issue":"10","key":"10.1016\/j.jpsychires.2020.06.013_bib19","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/phar.1313","article-title":"Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review","volume":"33","author":"Gentile","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.jpsychires.2020.06.013_bib20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/pcn.12824","article-title":"Discontinuation rates during long-term, second-generation antipsychotic long-acting injection treatment: a systematic review","volume":"73","author":"Gentile","year":"2019","journal-title":"Psychiatr. Clin. Neurosci."},{"issue":"5","key":"10.1016\/j.jpsychires.2020.06.013_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/YIC.0b013e32833948fa","article-title":"Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study","volume":"25","author":"Gopal","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2020.06.013_bib23","doi-asserted-by":"crossref","unstructured":"Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (n.d.). Schizophrenia and increased risks of cardiovascular disease. https:\/\/doi.org\/10.1016\/j.ahj.2005.02.007.","DOI":"10.1016\/j.ahj.2005.02.007"},{"key":"10.1016\/j.jpsychires.2020.06.013_bib24","author":"Higgins"},{"key":"10.1016\/j.jpsychires.2020.06.013_bib25","first-page":"140","article-title":"Development and psychometric validation of the clinical assessment Interview for negative symptoms","volume":"132","author":"Horan","year":"2011","journal-title":"CAINS"},{"issue":"2\u20133","key":"10.1016\/j.jpsychires.2020.06.013_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","article-title":"Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"116","author":"Hough","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2020.06.013_bib27","first-page":"939","volume":"vol. 394","author":"Huhn","year":"2019"},{"issue":"1","key":"10.1016\/j.jpsychires.2020.06.013_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-244X-12-27","article-title":"Choice of antipsychotic treatment by European psychiatry trainees\u00a0: are decisions based on evidence\u00a0?","volume":"12","author":"Jauhar","year":"2012","journal-title":"BMC Psychiatr."},{"issue":"Suppl. 52","key":"10.1016\/j.jpsychires.2020.06.013_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1192\/bjp.195.52.s7","article-title":"Historical perspective on antipsychotic long-acting injections","volume":"195","author":"Johnson","year":"2009","journal-title":"Br. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.jpsychires.2020.06.013_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00406-015-0596-y","article-title":"Pharmacological treatment of negative symptoms in schizophrenia","volume":"265","author":"J\u00fcrgen","year":"2015","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"issue":"6","key":"10.1016\/j.jpsychires.2020.06.013_bib31","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","article-title":"Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic","volume":"160","author":"Kane","year":"2003","journal-title":"Am. J. Psychiatr."},{"issue":"5","key":"10.1016\/j.jpsychires.2020.06.013_bib32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4088\/JCP.11m07530","article-title":"Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study","volume":"73","author":"Kane","year":"2012","journal-title":"J. Clin. Psychiatr."},{"issue":"11","key":"10.1016\/j.jpsychires.2020.06.013_bib33","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.4088\/JCP.14m09168","article-title":"Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study","volume":"75","author":"Kane","year":"2014","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2020.06.013_bib34","volume":"vol. 13","author":"Kay","year":"1982"},{"issue":"3","key":"10.1016\/j.jpsychires.2020.06.013_bib35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/pnp.428","article-title":"Factors important to psychiatrists when prescribing depot antipsychotics","volume":"20","author":"Kenicer","year":"2016","journal-title":"Prog. Neurol. Psychiatr."},{"issue":"2","key":"10.1016\/j.jpsychires.2020.06.013_bib36","first-page":"300","volume":"37","author":"Kirkpatrick","year":"2011","journal-title":"Brief. Negative Sympt. Scale Psychometr. Propert."},{"issue":"4","key":"10.1016\/j.jpsychires.2020.06.013_bib37","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/schbul\/sbx064","article-title":"Primary, enduring negative symptoms: An update on research","volume":"43","author":"Kirkpatrick","year":"2017","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.jpsychires.2020.06.013_bib38","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/schbul\/sbw043","article-title":"Mortality risk associated with long-acting injectable Antipsychotics: a systematic review and meta-analyses of randomized controlled trials","volume":"42","author":"Kishi","year":"2016","journal-title":"Schizophr. Bull."},{"issue":"10","key":"10.1016\/j.jpsychires.2020.06.013_bib39","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4088\/JCP.13r08440","article-title":"Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies","volume":"74","author":"Kishimoto","year":"2013","journal-title":"J. Clin. Psychiatr."},{"issue":"2\u20133","key":"10.1016\/j.jpsychires.2020.06.013_bib40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.schres.2004.05.006","article-title":"Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia","volume":"72","author":"Lauriello","year":"2005","journal-title":"Schizophr. Res."},{"issue":"Suppl. 438","key":"10.1016\/j.jpsychires.2020.06.013_bib41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0447.2008.01308.x","article-title":"Definitions of response and remission in schizophrenia: recommendations for their use and their presentation","volume":"119","author":"Leucht","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"issue":"1\u20133","key":"10.1016\/j.jpsychires.2020.06.013_bib42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","article-title":"Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials","volume":"127","author":"Leucht","year":"2011","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.jpsychires.2020.06.013_bib43","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.pnpbp.2011.02.001","article-title":"A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia","volume":"35","author":"Li","year":"2011","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatr."},{"issue":"7","key":"10.1016\/j.jpsychires.2020.06.013_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.jpsychires.2020.06.013_bib45","series-title":"Practical Meta-Analysis","author":"Lipsey","year":"2000"},{"key":"10.1016\/j.jpsychires.2020.06.013_bib46","article-title":"The current conceptualization of negative symptoms in schizophrenia","volume":"14\u201324","author":"Marder","year":"2017","journal-title":"February"},{"issue":"5","key":"10.1016\/j.jpsychires.2020.06.013_bib47","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.euroneuro.2013.10.016","article-title":"De fi ning and measuring negative symptoms of schizophrenia in clinical trials","volume":"24","author":"Marder","year":"2014","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.jpsychires.2020.06.013_bib48","volume":"6","author":"Mari","year":"2009"},{"issue":"5","key":"10.1016\/j.jpsychires.2020.06.013_bib49","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00127-004-0762-4","article-title":"Schizophrenia and employment","volume":"39","author":"Marwaha","year":"2004","journal-title":"Soc. Psychiatr. Psychiatr. Epidemiol."},{"issue":"19","key":"10.1016\/j.jpsychires.2020.06.013_bib50","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1001\/jama.2014.4310","article-title":"Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial","volume":"311","author":"McEvoy","year":"2014","journal-title":"JAMA J. Am. Med. Assoc."},{"issue":"11","key":"10.1016\/j.jpsychires.2020.06.013_bib51","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1503\/cmaj.1031981","article-title":"Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic)","volume":"171","author":"McGinn","year":"2004","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"issue":"8","key":"10.1016\/j.jpsychires.2020.06.013_bib52","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.4088\/JCP.14m09741","article-title":"A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia","volume":"76","author":"Meltzer","year":"2015","journal-title":"J. Clin. Psychiatr."},{"issue":"1\u20132","key":"10.1016\/j.jpsychires.2020.06.013_bib53","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.schres.2015.07.007","article-title":"Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia","volume":"168","author":"Naber","year":"2015","journal-title":"Schizophr. Res."},{"issue":"10","key":"10.1016\/j.jpsychires.2020.06.013_bib54","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/npp.2010.79","article-title":"A controlled, evidence-based trial of paliperidone palmitate, a Long-acting injectable antipsychotic, in schizophrenia","volume":"35","author":"Nasrallah","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"2\u20133","key":"10.1016\/j.jpsychires.2020.06.013_bib55","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.psychres.2009.05.004","article-title":"Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia","volume":"176","author":"Novick","year":"2010","journal-title":"Psychiatr. Res."},{"issue":"10039","key":"10.1016\/j.jpsychires.2020.06.013_bib56","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jpsychires.2020.06.013_bib57","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","article-title":"A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia","volume":"35","author":"Pandina","year":"2011","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatr."},{"issue":"4","key":"10.1016\/j.jpsychires.2020.06.013_bib58","doi-asserted-by":"crossref","first-page":"361","DOI":"10.9758\/cpn.2018.16.4.361","article-title":"Comparative efficacy and safety of long-Acting injectable and oral second-generation antipsychotics for the treatment of schizophrenia: a systematic review and meta-Analysis","volume":"16","author":"Park","year":"2018","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.jpsychires.2020.06.013_bib59","series-title":"DistillerSR. Evidence Partners","author":"Partners","year":"2016"},{"issue":"8","key":"10.1016\/j.jpsychires.2020.06.013_bib60","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/070674370605100808","article-title":"Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity","volume":"51","author":"Rubio","year":"2006","journal-title":"Can. J. Psychiatr."},{"issue":"6","key":"10.1016\/j.jpsychires.2020.06.013_bib61","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1192\/bjp.bp.109.069328","article-title":"An early improvement threshold to predict response and remission in first-episode schizophrenia","volume":"196","author":"Schennach-Wolff","year":"2010","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2020.06.013_bib62","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jpsychires.2020.06.013_bib63","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.schbul.a007076","article-title":"Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors","volume":"30","author":"Valenstein","year":"2004","journal-title":"Schizophr. Bull."},{"issue":"10","key":"10.1016\/j.jpsychires.2020.06.013_bib64","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.4088\/JCP.v67n1008","article-title":"Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review","volume":"67","author":"Valenstein","year":"2006","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2020.06.013_bib65","series-title":"WHO Collaborating Centre for Drug Statistics Methodology. ATC\/DDD Index\u2014antipsychotics","year":"2018"},{"key":"10.1016\/j.jpsychires.2020.06.013_bib66","author":"World Health Organization"},{"issue":"9","key":"10.1016\/j.jpsychires.2020.06.013_bib67","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2215-0366(17)30270-5","article-title":"Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses","volume":"4","author":"Zhu","year":"2017","journal-title":"Lancet Psychiatr."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395620308451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395620308451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:18:14Z","timestamp":1758367094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395620308451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":66,"alternative-id":["S0022395620308451"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2020.06.013","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2020.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}